44
Participants
Start Date
November 6, 2009
Primary Completion Date
July 25, 2014
Study Completion Date
July 25, 2014
Blood sampling
Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
Engerix-B
Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
Havrix
Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
GSK Investigational Site, Wilrijk
Lead Sponsor
GlaxoSmithKline
INDUSTRY